Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615675 | 0.90 | KDM4C (0.51) | KDM4C | |
| SCHEMBL17615629 | 0.89 | KDM4C (0.52) | KDM4CALDH1A1 | |
| SCHEMBL17615662 | 0.89 | KDM4C (0.50) | KDM4CROCK2ROCK1 | |
| SCHEMBL17615670 | 0.89 | KDM4C (0.50) | KDM4C | |
| SCHEMBL17602057 | 0.88 | KDM4C (0.63) | KDM4C | |
| SCHEMBL17615742 | 0.87 | KDM4C (0.52) | KDM4CGBA1 | |
| SCHEMBL24429083 | 0.85 | KDM4C (0.43) | KDM4CROCK2ALDH1A1LMNAMAPT | |
| SCHEMBL17602086 | 0.84 | KDM4C (0.64) | KDM4C | |
| SCHEMBL17615735 | 0.84 | KDM4C (0.57) | KDM4C | |
| SCHEMBL17615671 | 0.84 | KDM4C (0.46) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11535616-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10815234-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10208039-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10202381-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | KDM4C 9/4885ROCK2 1126/4885ALDH1A1 392/4885 |
| US-10030017-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885ROCK2 1126/4885ALDH1A1 392/4885 |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-11535616-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | KDM4C 9/4885ROCK2 1126/4885ALDH1A1 392/4885 |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-10202381-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885ROCK2 1126/4885ALDH1A1 392/4885 |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-10815234-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885ROCK2 1180/4885ALDH1A1 392/4885 |
| US-10208039-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885ROCK2 1126/4885ALDH1A1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.